Skip to main content

Table 2 Association of Polymorphisms cMyc-N11S and p27-V109G with Breast Cancer Risk

From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis

  Total White
  Cases (N = 1,115) Controls (N = 710) Unadjusted OR (95% CI) Age and race-adjusted OR (95% CI) Cases (N = 1,079) Controls (N = 677) Unadjusted OR (95% CI) Age-adjusted OR (95% CI)
cMyc-N11S (A>G)         
AA 1011 (91.9%) 653 (91.8%) 1.00 1.00 976 (91.7%) 621 (91.7%) 1.00 1.00
AG/GG 89 (8.1%) 57 (8.0%) 1.00 (0.71–1.43) 1.15 (0.73–1.82) 88 (8.4%) 56 (8.3%) 1.00 (0.71–1.42) 1.18 (0.75–1.87)
p27-V109G (T>G)         
TT 668 (61.5%) 405 (59.8%) 1.00 1.00 644 (61.1%) 393 (59.7%) 1.00 1.00
TG 366 (33.7%) 243 (35.9%) 0.91 (0.75–1.12) 0.70 (0.52–0.93) 359 (34.1%) 238 (36.2%) 0.92 (0.75–1.13) 0.71 (0.53–0.94)
GG 53 (4.9%) 29 (4.3%) 1.11 (0.69–1.77) 0.83 (0.42–1.65) 51 (4.8%) 27 (4.1%) 1.15 (0.71–1.87) 0.84 (0.42–1.67)
Combined         
cMyc AA + p27 TT 611 (56.4%) 369 (54.5%) 1.00 1.00 588 (56.0%) 357 (54.3%) 1.00 1.00
cMyc AA + p27 TG/GG 386 (35.6%) 253 (37.4%) 0.92 (0.75–1.13) 0.92 (0.74–1.13) 377 (35.9%) 246 (37.4%) 0.93 (0.76–1.15) 0.70 (0.52–0.94)
cMyc AG/GG + p27 TT 55 (5.1%) 36 (5.3%) 0.92 (0.59–1.43) 0.96 (0.61–1.51) 54 (5.1%) 36 (5.5%) 0.91 (0.59–1.42) 0.98 (0.55–1.74)
cMyc AG/GG + p27 TG/GG 32 (3.0%) 19 (2.8%) 1.02 (0.57–1.82) 1.08 (0.59–1.98) 32 (3.0%) 19 (2.9%) 1.02 (0.57–1.83) 0.99 (0.45–2.19)